🚀 VC round data is live in beta, check it out!
Vetoquinol Valuation Multiples
Discover revenue and EBITDA valuation multiples for Vetoquinol and similar public comparables like uniQure, UroGen Pharma, Collegium Pharmaceutical, Xeris Biopharma and more.
Vetoquinol Overview
About Vetoquinol
Vetoquinol SA operates is a France-based firm serving in the healthcare market. Its focus lies on developing and marketing veterinary drugs mainly in the European region and to a certain extent in America and Asia. Its portfolio of drugs entails anti-infectives, anti- pain inflammatory drugs, cardiovascular and nephrology treatment intended mainly for pets and livestock.
Founded
1933
HQ
Employees
2.1K
Website
Financials (LTM)
EV
$910M
Vetoquinol Financials
Vetoquinol reported last 12-month revenue of $612M and EBITDA of $127M.
In the same LTM period, Vetoquinol generated $127M in EBITDA and $72M in net income.
Revenue (LTM)
Vetoquinol P&L
In the most recent fiscal year, Vetoquinol reported revenue of $635M and EBITDA of $134M.
Vetoquinol expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $612M | XXX | $635M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $457M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 72% | XXX | XXX | XXX |
| EBITDA | $127M | XXX | $134M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 21% | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $72M | XXX | $69M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 11% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Vetoquinol Stock Performance
Vetoquinol has current market cap of $1B, and enterprise value of $910M.
Market Cap Evolution
Vetoquinol's stock price is $93.79.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $910M | $1B | -0.7% | XXX | XXX | XXX | $5.86 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVetoquinol Valuation Multiples
Vetoquinol trades at 1.5x EV/Revenue multiple, and 7.2x EV/EBITDA.
EV / Revenue (LTM)
Vetoquinol Financial Valuation Multiples
As of April 18, 2026, Vetoquinol has market cap of $1B and EV of $910M.
Equity research analysts estimate Vetoquinol's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vetoquinol has a P/E ratio of 15.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $910M | XXX | $910M | XXX | XXX | XXX |
| EV/Revenue | 1.5x | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | 7.2x | XXX | 6.8x | XXX | XXX | XXX |
| EV/EBIT | 9.1x | XXX | 10.1x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 2.0x | XXX | XXX | XXX |
| P/E | 15.4x | XXX | 16.0x | XXX | XXX | XXX |
| EV/FCF | 14.3x | XXX | 11.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Vetoquinol Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Vetoquinol Margins & Growth Rates
Vetoquinol's revenue in the last 12 month grew by 4%.
Vetoquinol's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Vetoquinol's rule of 40 is 25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Vetoquinol's rule of X is 30% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Vetoquinol Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | (5%) | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | (7%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 25% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 30% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 14% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 58% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Vetoquinol Public Comps
See public comps and valuation multiples for other Pet Care and Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Vetoquinol | XXX | XXX | XXX | XXX | XXX | XXX |
| uniQure | XXX | XXX | XXX | XXX | XXX | XXX |
| UroGen Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Collegium Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Xeris Biopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Aktis Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vetoquinol M&A Activity
Vetoquinol acquired XXX companies to date.
Last acquisition by Vetoquinol was on XXXXXXXX, XXXXX. Vetoquinol acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Vetoquinol
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialVetoquinol Investment Activity
Vetoquinol invested in XXX companies to date.
Vetoquinol made its latest investment on XXXXXXXX, XXXXX. Vetoquinol invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Vetoquinol
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Vetoquinol
| When was Vetoquinol founded? | Vetoquinol was founded in 1933. |
| Where is Vetoquinol headquartered? | Vetoquinol is headquartered in France. |
| How many employees does Vetoquinol have? | As of today, Vetoquinol has over 2K employees. |
| Who is the CEO of Vetoquinol? | Vetoquinol's CEO is Matthieu Frechin. |
| Is Vetoquinol publicly listed? | Yes, Vetoquinol is a public company listed on Euronext Paris. |
| What is the stock symbol of Vetoquinol? | Vetoquinol trades under VETO ticker. |
| When did Vetoquinol go public? | Vetoquinol went public in 2006. |
| Who are competitors of Vetoquinol? | Vetoquinol main competitors are uniQure, UroGen Pharma, Collegium Pharmaceutical, Xeris Biopharma. |
| What is the current market cap of Vetoquinol? | Vetoquinol's current market cap is $1B. |
| What is the current revenue of Vetoquinol? | Vetoquinol's last 12 months revenue is $612M. |
| What is the current revenue growth of Vetoquinol? | Vetoquinol revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Vetoquinol? | Current revenue multiple of Vetoquinol is 1.5x. |
| Is Vetoquinol profitable? | Yes, Vetoquinol is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Vetoquinol? | Vetoquinol's last 12 months EBITDA is $127M. |
| What is Vetoquinol's EBITDA margin? | Vetoquinol's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Vetoquinol? | Current EBITDA multiple of Vetoquinol is 7.2x. |
| What is the current FCF of Vetoquinol? | Vetoquinol's last 12 months FCF is $63M. |
| What is Vetoquinol's FCF margin? | Vetoquinol's last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of Vetoquinol? | Current FCF multiple of Vetoquinol is 14.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.